Cargando…
P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
Autores principales: | Kersting, Sabina, Levin, Mark-David, Dubois, Julie, van Norden, Yvette, Dobber, Johan, Jauw, Yvonne, van der Kevie-Kersemaekers, Anne-Marie, Mellink, Clemens, Da Cunha-Bang, Caspar, Van Desr Burg, Leonie, Te Raa, Doreen, de Boer, Fransien, Droogendijk, Jolanda, Idink, Cecile, De Heer, Koen, Nijziel, Marten, Tick, Lidwine, Ludwig, Inge, Silbermann, Mathijs, Beeker, Aart, Bellido, Mar, Evers, Ludo, Zwezerijnen, Gerben, Zijlstra, Josée, Kap, Marcel, Niemann, Carsten, Kater, Arnon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429648/ http://dx.doi.org/10.1097/01.HS9.0000969380.79786.1a |
Ejemplares similares
-
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
por: Rijneveld, Anita W., et al.
Publicado: (2022) -
P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, Kaz, et al.
Publicado: (2023) -
S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
por: Urban, Aleksandra, et al.
Publicado: (2023) -
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial
por: Chamuleau, Martine E.D., et al.
Publicado: (2019) -
Two Cases of Q-Fever in Hairy Cell Leukemia
por: Ammatuna, Emanuele, et al.
Publicado: (2014)